GS-7977: A promising nucleotide analog NS5B polymerase inhibitor of HCV

Valérie Martel-Laferrière, Douglas T. Dieterich

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Despite the approval of the protease inhibitors telaprevir and boceprevir, the treatment of hepatitis C remains difficult to manage and sustained virologic response rates have room for further improvement. GS-7977 is a nucleotide analog NS5B inhibitor currently in Phase III trials. It offers great hope in addressing the problems currently associated with pegylated interferon and protease inhibitor-based therapies. The purpose of this article is to review the development of GS-7977, the information currently available in the public domain concerning its pharmacokinetic, clinical efficacy and side-effect profile, and to evaluate the future of this drug and its integration into the hepatitis C treatment paradigm.

Original languageEnglish
Pages (from-to)537-546
Number of pages10
JournalFuture Virology
Issue number6
StatePublished - Jun 2012


  • GS-7977
  • GS-9851
  • NS5B polymerase inhibitor
  • PSI-7977
  • hepatitis C
  • nucleotide analog


Dive into the research topics of 'GS-7977: A promising nucleotide analog NS5B polymerase inhibitor of HCV'. Together they form a unique fingerprint.

Cite this